Drug Profile
Suvemcitug - Simcere Pharmaceutical Group
Alternative Names: Anti-VEGF monoclonal antibody - Pyxis Oncology; APX-003; BD-0801; EP-10030; Sevacizumab - Pyxis Oncology; SIM-BD-0801Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Epitomics
- Developer Jiangsu T-mab BioPharma; Simcere Pharmaceutical Group
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase II Colorectal cancer; Solid tumours
- Discontinued Wet age-related macular degeneration
Most Recent Events
- 13 Mar 2024 Jiangsu Simcere Pharmaceutical terminated a phase II trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (SC), due to the sponsor's research and development strategy adjustment (NCT05148195)
- 01 Nov 2023 Phase-III clinical trials in Fallopian tube cancer in China (IV) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)
- 01 Nov 2023 Phase-III clinical trials in Ovarian cancer in China (IV) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)